BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Intelligence Buyer Seller Date Upfront cash ($M) Upfront stock ($M) Milestones ($M) Disclosed value ($M) Bracco...
BioCentury | Jun 27, 2019
Financial News

Syncona reaps tenfold return from Blue Earth exit

...scale, and will also drive new company launches, the firm's CEO Martin Murphy told BioCentury. Bracco...
...89% stake in Blue Earth, and expects a net return of £337 million ($428.9 million). Bracco...
...gene therapy company Nightstar Therapeutics plc (NASDAQ:NITE) this year (see "Biogen to Acquire Nightstar" ). Bracco...
BioCentury | Aug 17, 2015
Clinical News

Vitaros alprostadil regulatory update

...Vitaros in Spain, Russia, Turkey, Ireland and certain other European and undisclosed countries in Africa. Bracco S.p.A....
BioCentury | Oct 20, 2014
Clinical News

Sulfur hexafluoride lipid-type A microspheres regulatory update

...FDA approved Lumason sulfur hexafluoride lipid-type A microspheres from Bracco as an ultrasound contrast agent. The...
...reactions. The product is marketed as SonoVue outside the U.S., including countries in the EU. Bracco...
BioCentury | Feb 3, 2014
Clinical News

Vitaros alprostadil regulatory update

...see BioCentury, Jan. 6). Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Jan 6, 2014
Clinical News

Vitaros alprostadil regulatory update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Jan 6, 2014
Company News

Apricus Biosciences, Novartis sales and marketing update

...commercialize Vitaros in the U.K., Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, Bracco S.p.A....
BioCentury | Dec 9, 2013
Clinical News

Vitaros alprostadil regulatory update

...market the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, Bracco S.p.A....
BioCentury | Nov 25, 2013
Company News

Apricus Biosciences, Laboratoires Majorelle sales and marketing update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Oct 14, 2013
Clinical News

Vitaros alprostadil regulatory update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights and Bracco S.p.A....
Items per page:
1 - 10 of 54
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...Intelligence Buyer Seller Date Upfront cash ($M) Upfront stock ($M) Milestones ($M) Disclosed value ($M) Bracco...
BioCentury | Jun 27, 2019
Financial News

Syncona reaps tenfold return from Blue Earth exit

...scale, and will also drive new company launches, the firm's CEO Martin Murphy told BioCentury. Bracco...
...89% stake in Blue Earth, and expects a net return of £337 million ($428.9 million). Bracco...
...gene therapy company Nightstar Therapeutics plc (NASDAQ:NITE) this year (see "Biogen to Acquire Nightstar" ). Bracco...
BioCentury | Aug 17, 2015
Clinical News

Vitaros alprostadil regulatory update

...Vitaros in Spain, Russia, Turkey, Ireland and certain other European and undisclosed countries in Africa. Bracco S.p.A....
BioCentury | Oct 20, 2014
Clinical News

Sulfur hexafluoride lipid-type A microspheres regulatory update

...FDA approved Lumason sulfur hexafluoride lipid-type A microspheres from Bracco as an ultrasound contrast agent. The...
...reactions. The product is marketed as SonoVue outside the U.S., including countries in the EU. Bracco...
BioCentury | Feb 3, 2014
Clinical News

Vitaros alprostadil regulatory update

...see BioCentury, Jan. 6). Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Jan 6, 2014
Clinical News

Vitaros alprostadil regulatory update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Jan 6, 2014
Company News

Apricus Biosciences, Novartis sales and marketing update

...commercialize Vitaros in the U.K., Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, Bracco S.p.A....
BioCentury | Dec 9, 2013
Clinical News

Vitaros alprostadil regulatory update

...market the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, Bracco S.p.A....
BioCentury | Nov 25, 2013
Company News

Apricus Biosciences, Laboratoires Majorelle sales and marketing update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights, and Bracco S.p.A....
BioCentury | Oct 14, 2013
Clinical News

Vitaros alprostadil regulatory update

...the drug in Germany. Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) has U.S. commercialization rights and Bracco S.p.A....
Items per page:
1 - 10 of 54